A medtech innovator has accelerated its R&D and manufacture of its ground-breaking cancer treatment, after funding from Innovate UK’s Analysis for Innovators (A4I) programme.
LightOx, based in Newcastle, has developed a UK-first early-stage mouth cancer treatment using light-activated chemotherapy. The treatment involves a gel being applied to the affected area and the drug activated with light. It is undergoing preclinical testing, is quick, simple and non-invasive with fewer side effects than surgery and significantly improves the overall patient experience.…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
